JP5080263B2 - 勃起不全の治療のためのプロピオニルｌ−カルニチンおよびシルデナフィルと組み合わせてのアセチルｌ−カルニチンの使用 - Google Patents

勃起不全の治療のためのプロピオニルｌ−カルニチンおよびシルデナフィルと組み合わせてのアセチルｌ−カルニチンの使用 Download PDF

Info

Publication number
JP5080263B2
JP5080263B2 JP2007540521A JP2007540521A JP5080263B2 JP 5080263 B2 JP5080263 B2 JP 5080263B2 JP 2007540521 A JP2007540521 A JP 2007540521A JP 2007540521 A JP2007540521 A JP 2007540521A JP 5080263 B2 JP5080263 B2 JP 5080263B2
Authority
JP
Japan
Prior art keywords
carnitine
acid
acetyl
propionyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007540521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531466A5 (https=
JP2008531466A (ja
Inventor
アレアルド・コヴェレッチ
ジョルジョ・カヴァッリーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2008531466A publication Critical patent/JP2008531466A/ja
Publication of JP2008531466A5 publication Critical patent/JP2008531466A5/ja
Application granted granted Critical
Publication of JP5080263B2 publication Critical patent/JP5080263B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007540521A 2004-11-11 2005-10-19 勃起不全の治療のためのプロピオニルｌ−カルニチンおよびシルデナフィルと組み合わせてのアセチルｌ−カルニチンの使用 Expired - Fee Related JP5080263B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2004A000561 2004-11-11
IT000561A ITRM20040561A1 (it) 2004-11-11 2004-11-11 Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
PCT/EP2005/011238 WO2006050794A1 (en) 2004-11-11 2005-10-19 Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction

Publications (3)

Publication Number Publication Date
JP2008531466A JP2008531466A (ja) 2008-08-14
JP2008531466A5 JP2008531466A5 (https=) 2008-12-04
JP5080263B2 true JP5080263B2 (ja) 2012-11-21

Family

ID=35501123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540521A Expired - Fee Related JP5080263B2 (ja) 2004-11-11 2005-10-19 勃起不全の治療のためのプロピオニルｌ−カルニチンおよびシルデナフィルと組み合わせてのアセチルｌ−カルニチンの使用

Country Status (16)

Country Link
US (1) US8003652B2 (https=)
EP (1) EP1811988B1 (https=)
JP (1) JP5080263B2 (https=)
KR (1) KR101455275B1 (https=)
AT (1) ATE456950T1 (https=)
CA (1) CA2585654C (https=)
CY (1) CY1110239T1 (https=)
DE (1) DE602005019251D1 (https=)
DK (1) DK1811988T3 (https=)
ES (1) ES2339265T3 (https=)
IT (1) ITRM20040561A1 (https=)
MX (1) MX2007005518A (https=)
PL (1) PL1811988T3 (https=)
PT (1) PT1811988E (https=)
SI (1) SI1811988T1 (https=)
WO (1) WO2006050794A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010222347A (ja) * 2009-02-24 2010-10-07 Daiichi Sankyo Healthcare Co Ltd Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
WO2018070971A1 (ru) * 2016-10-10 2018-04-19 Товарыство З Обмэжэною Видповидальнистю Науково-Выробныча Фирма "Микрохим" Фармацевтическая композиция в форме оромукозного спрея для лечения эректильной дисфункции и легочной артериальной гипертензии

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE462791T1 (de) 1999-08-13 2010-04-15 Deutsches Krebsforsch Parvovirus ns1 varianten
IT1306722B1 (it) * 1999-10-08 2001-10-02 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disfunzionicircolatorie, comprendente derivati della l-carnitina ed estratti di
JP2001233770A (ja) * 2000-02-23 2001-08-28 Dountsuendorufaa Udo 勃起機能不全治療用の経口薬の組合わせ
ITRM20010621A1 (it) * 2001-10-18 2003-04-18 Aldo Fassi Sali metallici non igroscopici e idrosolubili di alcanoil l-carnitine, integratori dietetici che li contengono e kit dietetici, per contrast
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Also Published As

Publication number Publication date
EP1811988A1 (en) 2007-08-01
CY1110239T1 (el) 2015-01-14
MX2007005518A (es) 2007-05-18
KR20070085961A (ko) 2007-08-27
DK1811988T3 (da) 2010-05-17
ES2339265T3 (es) 2010-05-18
CA2585654A1 (en) 2006-05-18
EP1811988B1 (en) 2010-02-03
SI1811988T1 (sl) 2010-10-29
WO2006050794A1 (en) 2006-05-18
PL1811988T3 (pl) 2010-07-30
ATE456950T1 (de) 2010-02-15
US8003652B2 (en) 2011-08-23
DE602005019251D1 (de) 2010-03-25
PT1811988E (pt) 2010-04-08
CA2585654C (en) 2013-04-02
KR101455275B1 (ko) 2014-10-27
JP2008531466A (ja) 2008-08-14
US20080090906A1 (en) 2008-04-17
ITRM20040561A1 (it) 2005-02-11

Similar Documents

Publication Publication Date Title
EP2786750B2 (en) Agent for reducing adverse side effects of kinase inhibitor
ES2626651T3 (es) Composiciones para el tratamiento de la fatiga crónica
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
TW200300091A (en) Dosage unit comprising a prostaglandin analog for treating constipation
US20150250761A1 (en) Compositions and methods for treatment of chronic fatigue
JP5080263B2 (ja) 勃起不全の治療のためのプロピオニルｌ−カルニチンおよびシルデナフィルと組み合わせてのアセチルｌ−カルニチンの使用
EP1569635B1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
HU229214B1 (hu) Propionil-L-karnitint és további hatóanyagokat tartalmazó kombinációs készítmény alkalmazása merevedési zavar kezelésére
US7776913B2 (en) Carnitines for treating or preventing disorders caused by andropause
US20140271908A1 (en) Dietary supplements and methods for preventing and treating migraines
CN100408038C (zh) 用来治疗原发性头痛的复合维生素的应用
EP4359077A1 (en) Dexmecamylamine and uses thereof
RU2336878C2 (ru) Средство для лечения эректильной дисфункции
KR0128705B1 (ko) 두통 예방 및 치료제 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120720

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120821

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120830

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150907

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5080263

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees